Cargando…
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Multiple myeloma (MM) is usually diagnosed in older adults at the time of immunosenescence, a collection of age-related changes in the immune system that contribute to increased susceptibility to infection and cancer. The MM tumor microenvironment and cumulative chemotherapies also add to defects in...
Autores principales: | Cooke, Rachel E., Koldej, Rachel, Ritchie, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481018/ https://www.ncbi.nlm.nih.gov/pubmed/31093282 http://dx.doi.org/10.1155/2019/2186494 |
Ejemplares similares
-
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma
por: Cooke, Rachel E., et al.
Publicado: (2016) -
Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells
por: Cooke, Rachel Elizabeth, et al.
Publicado: (2020) -
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020) -
How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment
por: Belgioia, Liliana, et al.
Publicado: (2020) -
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)